Hefei Lifeon Pharmaceutical (003020.SZ) plans to sign a cooperative agreement with Cube Investment for agent incubation.

Hefei Lifeon Pharmaceutical (003020.SZ) announced that due to the large investment, long cycle, and numerous factors involved in drug research and development, which are easily influenced by uncontrollable factors, the progress and results of research and development, as well as the future market competition situation of products, are uncertain. In order to reduce the company's investment risk, effectively seize business opportunities, and avoid competition in the same industry between the company's controlling shareholder and the company, while maximizing the protection of the interests of the company and all shareholders, especially small and medium shareholders, the company plans to sign a "Delegate Cultivation Agreement" with Levor Investment, entrusting Levor Investment to cultivate innovative drug research projects on behalf of the company according to market principles. The cultivation project is planned to use Nanjing Minovi Pharmaceutical Co., Ltd. (referred to as "Minovi" or "the target company") as the implementing entity. Levor Investment plans to acquire 20% equity in the target company through cash capital increase. The target company carries out drug research and development, production, and sales in the field of mental illness. After the drug meets the listing conditions, the company has the priority contract manufacturing rights for the drug in the mainland of the People's Republic of China under equal conditions.